Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
Sonja Ständer(Klinik für Schlafmedizin), Christophe Piketty(Galderma (Switzerland)), J.‐P. Lacour(Centre Hospitalier Universitaire de Nice), Adam Reich(Rzeszów University of Technology), Franz J. Legat(Medical University of Graz), Andreas Wollenberg(University Hospital Augsburg), C. Paul(Université Fédérale de Toulouse Midi-Pyrénées), Joanna Narbutt(ENT and Allergy), L. Misery(Centre Hospitalier Régional Universitaire de Brest), Thomas Bieber(CK-CARE), Faiz Ahmad(Galderma (United States)), Gil Yosipovitch(University of Miami)
Cited by 280
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries
|Journal of Investigative Dermatology|2014|954
Definition of treatment goals for moderate to severe psoriasis: a European consensus
|Archives of Dermatological Research|2010|892
Clinical Classification of Itch: a Position Paper of the International Forum for the Study of Itch
|Acta Dermato Venereologica|2007|748
Inefficacy of Immediate Node Dissection in Stage 1 Melanoma of the Limbs
|New England Journal of Medicine|1977|667